Shares in Petach Tikva, Israel headquartered Teva Pharmaceutical Industries Ltd ended Tuesday's session at $37.86, down 0.76% from the last trading session. The stock recorded a trading volume of 5.52 million shares. Shares of the Company, which develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide, are trading 12.74% below their 50-day moving average. Moreover, Teva Pharmaceutical Industries' stock has a Relative Strength Index (RSI) of 35.90.
On November 16th, 2016, research firm RBC Capital Markets reiterated its 'Outperform' rating on the Company's stock with a decrease of the target price from $58 a share to $51 a share.
On November 21st, 2016, Teva Pharmaceutical announced that it has obtained approval from the European Commission for an indication extension of Trisenox® (arsenic trioxide). This marks an important advancement in treatment for Acute Promyelocytic Leukemia (APL) patients in Europe, as it is the first time that a form of acute leukemia can be effectively treated with a regimen that is entirely chemotherapy-free. APL is a rare and aggressive type of acute leukemia that can kill within hours or days if left untreated. Trisenox®, in combination with retinoic acid, has shown a 99% overall survival rate with almost no relapses after more than four years of median follow-up. See our free and comprehensive research report on TEVA at:
Dublin, Ireland headquartered Endo International PLC's stock saw a drop of 3.00%, closing the day at $16.17 with a total trading volume of 3.37 million shares. Shares of the Company, which develops, manufactures, and distributes pharmaceutical products and devices worldwide, are trading 15.54% below their 50-day moving average. The stock has an RSI of 40.50.
On November 11th, 2016, research firm Mizuho reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $29 a share to $25 a share.
On November 17th, 2016, Endo International announced positive results from its Phase 2b study of collagenase clostridium histolyticum (CCH) for the treatment of edematous fibrosclerotic panniculopathy, commonly known as cellulite. CCH is known in its currently approved indications in the U.S. as XIAFLEX® for adult Dupuytren's contracture and Peyronie's disease. Trial subjects receiving CCH showed statistically significant levels of improvement in the appearance of cellulite with treatment, as measured by the trial's primary endpoint, compared to those subjects receiving placebo. ENDP free research report PDF is just a click away at:
On Tuesday, shares in Carlsbad, California headquartered Ionis Pharmaceuticals Inc. recorded a trading volume of 1.38 million shares. The stock ended the day 1.14% higher at $46.27. The Company's shares have surged 77.35% in the past month and 55.84% in the previous three months. The stock is trading above its 50-day and 200-day moving averages by 33.03% and 38.78%, respectively. Furthermore, shares of Ionis Pharma, which focuses on developing drugs for patients with severe and rare diseases, have an RSI of 67.21.
On November 10th, 2016, research firm Leerink Partners resumed its 'Market Perform' rating on the Company's stock.
On November 15th, 2016, Akcea Therapeutics, a wholly-owned subsidiary of Ionis Pharmaceuticals, announced positive results from an interim analysis of a Phase 1/2a study of IONIS-ANGPTL3-LRx. In this study, subjects with elevated triglycerides achieved substantial and statistically significant mean reductions in angiopoietin-like 3, triglycerides and LDL-cholesterol of up to 83%, 66%, and 35%, respectively. Sign up for your complimentary report on IONS at:
Alpharetta, Georgia headquartered Alimera Sciences Inc.'s stock saw a drop of 1.77%, finishing yesterday's session at $1.11. A total volume of 313,572 shares was traded, which was above their three months average volume of 258,690 shares. The Company's shares are trading below their 50-day moving average by 17.67%. Additionally, shares of Alimera Sciences, which engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the US, Germany, Portugal, and the UK, have an RSI of 34.69.
On November 02nd, 2016, Alimera's consolidated net revenues increased by $1.4 million, or 20%, to $8.3 million for Q3 2016, compared to consolidated net revenues of $6.9 million for Q3 2015. Alimera's GAAP net loss attributable to common stockholders for Q3 2016 was $9.2 million compared to $1.5 million for Q3 2015. Register for free on Stock-Callers.com and download the latest research report on ALIM at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA